About Multiple Sclerosis
Multiple sclerosis (MS):Multiple sclerosis (MS) is an unpredictable, often debilitating disease of the central nervous system (CNS) that disrupts the flow of information within the brain, and between the brain and the body.
An Uncertain Future
More than 2 million people in the world
400,000 in the US.
Most people diagnosed between the ages of 20 and 50.
Although not fully understood, demyelination of axons in the CNS is caused by the immune system attacking the myelin sheath.
Types of MS and Progression
Relapsing Remitting (RRMS)
Characterized by clearly defined attacks of new or increasing neurological symptoms called relapses or exacerbations
Relapses can be followed by periods of partial or complete recovery (remissions)
Secondary Progressive (SPMS)
Most people who are diagnosed with RRMS will eventually transition to a secondary progressive course in which there is a progressive worsening of neurologic function (accumulation of disability) over time.
Primary Progressive (PPMS)
Worsening neurologic function (accumulation of disability) from the onset of symptoms, without early relapses or remissions.
Signs and Symptoms
Weakness impaired mobility
Modulate the immune system to slow disease progression.
Currently there are no therapies that cause remyelination.
of patients diagnosed with RRMS advance to progressive MS within 19 years of diagnosis
ENDECE has discovered a drug with the ability to induce the process for restoring and repairing the myelin sheath.
A new drug with the potential to induce remyelination, the process for restoring and repairing the myelin sheath in demyelinating diseases including osmotic demyelination syndrome, transverse myelitis and multiple sclerosis.
For more information go to About NDC-1308
To learn more go to:
A new drug with the potential to induce remyelination in demyelinating diseases including
ODS / CPM / EPM and Multiple Sclerosis